Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving hydrolase
Reexamination Certificate
1999-11-12
2001-01-16
Leary, Louise N. (Department: 1623)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving hydrolase
C435S016000, C435S004000, C435S007100, C435S023000, C435S024000
Reexamination Certificate
active
06174696
ABSTRACT:
BACKGROUND OF THE INVENTION
Total concentration of homocysteine in body fluids, such as plasma or serum, is an important marker for disease. For example, homocysteine quantification can be an important risk indicator for cardiovascular disease, can be a sensitive marker of cobalamin and folate deficiencies, and can be used to diagnose in-born errors in metabolism known as homocystinuria. Homocysteine quantification has also been reported as useful in assessing birth defects in pregnant women and cognitive impairment in the elderly. See Frantzen, et al.,
Enzyme Conversion Immunoassay for Determining Total Homocysteine in Plasma or Serum,
Clinical Chemistry 44:2, 311-316 (1998). Current assays, such as those using HPLC or GC-MS, are expensive and require highly skilled technical staff. An efficient and accurate assay, that can be carried out without necessity for highly skilled personnel or complex analytical chemistry equipment, has been needed.
SUMMARY OF THE INVENTION
The present invention provides an assay for homocysteine found in plasma, serum or other body fluids of a patient. According to this assay, a homocysteine containing sample is condensed using an enzyme, cystathionine &bgr;-synthase, to form cystathionine. This cystathionine is subjected to another enzyme, cystathionine &bgr;-lyase, to release pyruvate and ammonia, and homocysteine. The total homocysteine concentration in the patient sample can be determined based on the detection and correlation of the pyruvate and/or ammonia released.
In another embodiment of the invention, the patient sample is subjected to treatment by dithiothreitol or other reducing agent, in appropriate amounts to produce free homocysteine in the sample.
In a still further embodiment, the enzymes cystathionine P-synthase and cystathionine &bgr;-lyase may be treated with a phosphorylated form of vitamin B6 in order to optimize their function in the assay of the invention.
A still further embodiment of the present invention is a kit for determining homocysteine concentration in a sample that includes the enzymes cystathionine &bgr;-synthase and cystathionine &bgr;-lyase, and serine. Such kit may further include a reducing agent such as dithiothreitol (DTT), and an enzyme co-factor such as pyridoxal 5′ phosphate (PLP).
REFERENCES:
patent: 4940658 (1990-07-01), Allen et al.
patent: 5374560 (1994-12-01), Allen et al.
patent: 5438017 (1995-08-01), Allen et al.
patent: 5457055 (1995-10-01), Allen et al.
patent: 5478729 (1995-12-01), Van Atta et al.
patent: 5523225 (1996-06-01), Kraus
patent: 5631127 (1997-05-01), Sundrehagen
patent: 5715835 (1998-02-01), Lishko et al.
patent: 5827645 (1998-10-01), Sundrehagen
patent: 5958717 (1999-09-01), Sundrehagen
patent: 6046017 (2000-04-01), Schirch
patent: 6063581 (2000-05-01), Asa
patent: 6066467 (2000-05-01), Xu et al.
patent: WO 98/07872 (1998-02-01), None
patent: WO 99/05311 (1999-02-01), None
Stampfer, M. et al., “A Prospective Study of Plasma Homocyst(e)ine and Risk of Myocardial Infarction in US Physicians”,Journal of the American Medical Association, (Aug. 19, 1992) 268:7 877-881.
McCully, Kilmer S., “Homocysteine and Vascular Disease”,Nature Medicine, (Apr., 1996) 2:4 386-389.
Selhub, Jacob and Miller, Joshua W., “The pathogenesis of homocysteinemia: interruption of the coodinate regulation by S-adenosylmethionine of the remethylation and transsulfuration of homocysteine 1-4”,American Society for Clinical Nutrition, (1992), 55: 131-138.
Garg, Utam C. et al, “Short-term and long-term variability of plasma homocysteine measurement”,Clinical Chemistry, (1997) 43:1 141-145.
Malinow, M. Rene, “Plasma Homocyst(e)ine and Arterial Occlusive Diseases: A Mini-Review”,Clinical Chemistry,(1994) 40:1, 173-176.
“Bringing Homocysteine Into your Lab”,Clinical Laboratory Strategies,(Sep. 1998) 3:9 1-2.
Dudman, Nicholas P.B. et al., “Assay of plasma homocysteine: light sensitivity of the fluorescent 7-benzy-2-oxa-1, 3-diazole-4-sulfonic acid derivative, and use of appropriate calibrators”,Clinical Chemistry, (1996) 42:12 2028-2032.
Frantzen, Frank et al., “Enzyme conversion immunoassay for determining total homocysteine in plasma or serum”,Clinical Chemistry, (1998) 44:2 311-316.
Hankey, Graeme J. and Eikelboom, John W., “Homocysteine and vascular disease”,The Lancet, (Jul. 31, 1999) 354:407-413.
Shipchandler, Mohammed T. and Moore, Edwin G., “Rapid, Fully Automated Measurement of Plasma Homocyst(e)ine with the Abbott IMx Analyzer”,Clinical Chemistry, (1995) 41:7 991-993.
Axis—Immunoassay for the measurement of Plasma Homocysteine; source unknown.
Fiskerstrand, Torunn et al., “Homocysteineand Other Thiols in Plasma and Urine: Automated Determination and Sample Stability”,Clinical Chemistry,39, 2, (1993) pp. 263-271.
Ueland, Per M. et al., “Total Homocysteinein Plasma or Serum: Methods and Clinical Applications”,Clinical Chemistry,39, 9, (1993) pp. 1764-1779.
PCT/US99/26989 International Search Report.
Dupre Jennifer L.
Genzyme Corporation
Leary Louise N.
LandOfFree
Method for the determination of homocysteine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for the determination of homocysteine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for the determination of homocysteine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2507260